PFE
Pfizer Inc. · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -3.8% ·
share flow -1.1% ·
net new positions -8.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 173 | +3 | 3.03B | $72.98B | +7 | −5 |
| Q1 2026 | 174 | -2 | 3.01B | $84.42B | +3 | −6 |
| Q4 2025 | 175 | 0 | 3.18B | $79.18B | +2 | −1 |
| Q3 2025 | 25 | -1 | 1.84B | $46.80B | +1 | −3 |
| Q2 2025 | 24 | -1 | 1.79B | $43.32B | n/a | −1 |
| Q1 2025 | 22 | +1 | 777.51M | $19.69B | +2 | −1 |
| Q4 2024 | 21 | +2 | 779.18M | $20.66B | +2 | n/a |
| Q3 2024 | 18 | -2 | 507.62M | $14.68B | n/a | −2 |
| Q2 2024 | 20 | n/a | 545.09M | $15.24B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 534.32M | +0.2% | $13.61B | 0.2% | ▲ Add | 2 | SEC ↗ ×7 |
| 2 | BlackRock ✦ (passive) | 497.43M | +0.5% | $12.67B | 0.2% | ▲ Add | 2 | SEC ↗ ×23 |
| 3 | State Street Global Advisors ✦ (passive) | 299.09M | +0.9% | $7.62B | 0.3% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 129.01M | +1.2% | $3.28B | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | Morgan Stanley ✦ | 74.77M | n/a | $1.91B | 0.1% | n/c | 1 | SEC ↗ ×18 |
| 6 | Wellington Management ✦ | 60.46M | -21.5% | $1.54B | 0.3% | ▼ Trim | 6 | SEC ↗ ×7 |
| 7 | JPMorgan Chase ✦ | 56.53M | n/a | $1.44B | 0.0% | n/c | 1 | SEC ↗ ×36 |
| 8 | Fisher Asset Management ✦ | 49.29M | +1.9% | $1.26B | 0.5% | ▲ Add | 6 | SEC ↗ |
| 9 | Goldman Sachs Group ✦ | 32.82M | n/a | $836.14M | 0.1% | n/c | 1 | SEC ↗ ×5 |
| 10 | Arrowstreet Capital ✦ | 18.57M | -0.8% | $473.05M | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 11 | Fidelity (FMR) ✦ | 14.40M | -18.9% | $366.94M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 12 | Capital World Investors ✦ | 14.15M | +2.1% | $360.46M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 12.04M | +7.0% | $306.87M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 14 | Citadel Advisors ✦ | 10.29M | -30.8% | $262.11M | 0.2% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | AQR Capital Management ✦ | 9.51M | +120.9% | $230.99M | 0.1% | ▲ Add | 6 | SEC ↗ ×8 |
| 16 | Marshall Wace ✦ | 6.98M | +1458.2% | $177.83M | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 17 | D. E. Shaw & Co. ✦ | 5.90M | +57.5% | $150.43M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 18 | Adage Capital Partners ✦ | 3.79M | -23.6% | $96.52M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 19 | Renaissance Technologies ✦ | 3.40M | +465.9% | $86.52M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 20 | Millennium Management ✦ | 1.76M | -87.5% | $44.75M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 1.47M | +62.8% | $37.51M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 22 | Fairfax Financial ✦ | 890.90K | +36.9% | $22.69M | 1.1% | ▲ Add | 6 | SEC ↗ |
| 23 | GAMCO Investors ✦ | 563.30K | -16.1% | $14.35M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 24 | Dodge & Cox ✦ | 93.01K | -13.8% | $2.37M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 25 | Two Sigma Investments ✦ | 75.93K | New | $1.93M | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Two Sigma Investments | $1.93M | 0.0% |
Exited
| Norges Bank | $2.27B | was 0.3% |
| Starboard Value | $207.06M | was 3.6% |
| Bridgewater Associates | $24.55M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 225.90K shares, $6,343 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · Chairman & CEO · 38.00K sh @ 26.34 · $1.00M
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology